Shopping Cart
- Remove All
- Your shopping cart is currently empty
Tidutamab (XmAb-18087) is a humanized bispecific antibody targeting the growth inhibitory receptor 2 (SSTR2) and T-cell binding domain (CD3) with antitumor activity for the study of gastric neurosecretory tumors.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $445 | In Stock | |
5 mg | $1,380 | In Stock | |
10 mg | $2,230 | In Stock | |
25 mg | $4,180 | In Stock | |
50 mg | $5,670 | In Stock |
Description | Tidutamab (XmAb-18087) is a humanized bispecific antibody targeting the growth inhibitory receptor 2 (SSTR2) and T-cell binding domain (CD3) with antitumor activity for the study of gastric neurosecretory tumors. |
Targets&IC50 | SSTR2+ CHO cells (human):2.2 μg/mL (ED50) |
In vitro | Tidutamab was able to bind to human SSTR2+ CHO cells in the concentration range of 0-100,000 ng/mL with an ED50 value of 2.2 μg/mL and mediated the killing of SSTR2+ target cells by T cells. [1] |
In vivo | In NSG mice, Tidutamab was able to stimulate killing of SSTR2+ A549 lung cancer tumors by human T cells after a single intraperitoneal injection at a dose of 3 mg/kg. [1] |
Alias | XmAb-18087, XmAb18087 |
Cas No. | 2148354-90-7 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.